Download DNB 2017 Dec HEMAT HEMAT Paper III Question Paper

Download Diplomate in National Board (DNB) 2017 Dec HEMAT HEMAT Paper III Previous Question Papers

FINAL EXAM
DECEMB ER 2017
Time
Max. Marks
NATIONAL BOARD OF EXAMINATIONS
HEMATOLOGY
PAPER-III
HEM/D/17/48/III
:3 hours
:100
Attempt all questions in order.
Each question carries 10 marks.
Read the question carefully and answer to the point neatly and legib/y.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space
Answer all the parts of a single question together.
Start the question to a question on a fresh page or leave adequate space between two answers.
Draw table/diagrams/f/owcharts wherever appropriate.
Write short notes on:
1.
WHO classification of acute leukemia 2016: 4+3+3
a)
b)
C)
What are the changes in ALL?
What are germ line malignancy?
How this classification is better than 2008
classification?
Thalassemia: 3+3+4
a)
b)
0)
Monitoring iron overload
Long term endocrinological complications and their
management
Hematopietic stem cell transplant in thalassemia
Allogenic hematopoietic stem cell transplantation (HSCT): 4+2+4
Haploidentical HSCT
Role of killer immunoglobulin like receptors.
Its role in therapy of AML.
Classification of vWD 3+3+4
Diagnosis of subtypes
Management of vWD
Hemophilia: 3+3+2+2
a)
b)
C)
0|)
Diagnosis of coagulations factor defects.
Newer FV||| replacement options.
How do you decide which factors to use?
Management of hemophiliac joint arthropathy
Hodgkin?s lymphoma: 3+3+4
a)
b)
0)
Role of PET-CT.
Risk adapted approach in the management of
Hodgkin?s lymphoma.
Place of hematopoietic stem cell transplantation in the
management algorithm.
.1.
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.

FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
DECEMB ER 2017
7. a) Lab approach to diagnose inherited thrombophilia. 3+4+3
b) ISTH guidelines for management of anti?phospholipic
syndrome
0) Neweranticoagulants
8. a) Causes of acquired platelet dyfunctions. 3+4+3
b) Newer anti platelet agents
0) Lab monitoring of anti platelet agents.
9. CML: 6+2+2
a) How will you manage CML patient?
b) |matinib resistance.
0) International standardization of BCR-ABL.
10. a) Approach to treatment with newer agents in multiple 4+3+3
myeloma
b) Therapeutic strategies in sickle cell anemia
0) Optimizing therapy in follicular lymphoma
*****
.2.
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.